In this video, Motley Fool health-care analyst David Williamson discusses the specifics of the deals, what Sanofi is gaining, why the market loves Alnylam, and why 2015, with half a dozen proof-of-concept trials reporting, will be a big year for the stock.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.